Alliance Pharma main competitors are Nektar Therapeutics, DURECT, and Acusphere.

Competitor Summary. See how Alliance Pharma compares to its main competitors:

  • Cambrex has the most employees (2,201).
  • Employees at Nektar Therapeutics earn more than most of the competitors, with an average yearly salary of $83,561.
  • The oldest company is Alcami, founded in 1979.
Work At Alliance Pharma?
A
Share Your Experience

Alliance Pharma vs competitors

Company
ascdesc
Founding Date
ascdesc
Zippia Score
ascdesc
Headquarters
ascdesc
# of Locations
ascdesc
Revenue
ascdesc
Employees
ascdesc
2008
3.9
Malvern, PA1$12.6B174
2008
4.2
Durham, NC1$3.7M44
1990
4.8
San Francisco, CA2$92.1M718
1994
4.5
Huntingtown, MD2$367.8M1,000
1981
4.4
East Rutherford, NJ6$532.1M2,201
1993
4.1
Lexington, MA1-118
1979
4.1
Wilmington, NC6$87.0M981
1998
4.1
Cupertino, CA3$19.3M88
1979
4.1
Wilmington, NC1$86.0M750
1987
3.6
New York, NY1$2.7M36
2007
4.2
Lexington, KY1$3.5M50
2002
4.5
Fort Lauderdale, FL1$162.9M900
2003
4.3
Oklahoma City, OK1$12.0M261
1994
4.0
Horsham, PA1$12.3M30

Rate Alliance Pharma's competitiveness in the market.

Zippia waving zebra

Alliance Pharma salaries vs Competitors

Among Alliance Pharma competitors, employees at Nektar Therapeutics earn the most with an average yearly salary of $83,561.

Compare Alliance Pharma Salaries VS Competitors

Company
ascdesc
Average Salary
ascdesc
Hourly Salary
ascdesc
Salary Score
ascdesc
A
Alliance Pharma
$80,141$38.53-
B
BioAgilytix
$61,477$29.56-
N
Nektar Therapeutics
$83,561$40.17-
P
Pharmaceutics International
$67,963$32.67-
C
Cambrex
$73,346$35.26-
A
Acusphere
$76,389$36.73-

Compare Alliance Pharma Job Title Salaries VS Competitors

Company
ascdesc
Highest Salary
ascdesc
Hourly Salary
ascdesc
A
Alliance Pharma
$72,779$34.99
N
Nektar Therapeutics
$100,878$48.50
D
DURECT
$87,612$42.12
A
AAIPharma Services Corp
$81,526$39.20
A
Alcami
$81,297$39.09
C
Cytovance Biologics
$78,465$37.72
A
Acusphere
$76,914$36.98
D
Delcath Systems
$74,169$35.66
P
Pharmaceutics International
$74,054$35.60
A
Actavis Laboratories FL, Inc.
$71,554$34.40
C
Coldstream Labs
$71,455$34.35
P
PMRS
$70,580$33.93
B
BioAgilytix
$70,515$33.90
C
Cambrex
$58,176$27.97
A

Do you work at Alliance Pharma?

Does Alliance Pharma effectively differentiate itself from competitors?

Alliance Pharma Jobs

Alliance Pharma demographics vs competitors

Compare Gender At Alliance Pharma Vs Competitors

Job TitleascdescMaleascFemaleascdesc
DURECT50%50%
Alcami51%49%
Nektar Therapeutics51%49%
Pharmaceutics International60%40%
Cambrex65%35%
Alliance Pharma78%22%
Male
Female
100%
75%
50%
25%
0%

Alliance Pharma: 78%

Alliance Pharma: 22%

Cambrex: 65%

Cambrex: 35%

Pharmaceutics International: 60%

Pharmaceutics International: 40%

Nektar Therapeutics: 51%

Nektar Therapeutics: 49%

Alcami: 51%

Alcami: 49%

DURECT: 50%

DURECT: 50%

0%
25%
50%
75%
100%

Compare Race At Alliance Pharma Vs Competitors

Company
ascdesc
White
ascdesc
Hispanic or Latino
ascdesc
Black or African American
ascdesc
Asian
ascdesc
Unknown
ascdesc
Diversity Score
ascdesc
54%4%7%32%3%
6.4
65%10%10%10%5%
7.4
37%19%7%28%9%
8.5
48%18%10%18%6%
9.7
66%7%13%9%4%
7.4
38%9%17%24%13%
9.4

Alliance Pharma REVENUE Vs Competitors

  • Alliance Pharma
  • Cambrex
  • DURECT
  • Nektar Therapeutics

Alliance Pharma And Similar Companies CEOs

CEOBio
T
Thomas Loewald
Cambrex

Mr. Loewald joined Cambrex in September 2020 and currently serves as Chief Executive Officer. Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including Chief Commercial Officer, President of the Analytical Instruments Group, President of the Laboratory Products Group, and President of the Laboratory Equipment and Environmental Instrument Divisions. Earlier in his career he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the Board of Directors of Harvard BioScience, a global developer, manufacturer and marketer of a broad range of solutions to advance life science.

G
Gerard J. Michel
Delcath Systems

Mr. Gerard J. Michel has served as our Chief Financial Officer, Vice President of Corporate Development and Treasurer, since November 2007. Prior to joining Biodel, Mr. Michel served in various roles at NPS Pharmaceuticals, most recently as its Chief Financial Officer and Vice President of Corporate Strategy. Previously, Mr. Michel was a principal with the consulting firm of Booz-Allen & Hamilton where he evaluated and solved strategic and operational issues for healthcare clients. Mr. Michel also served in marketing, sales, and corporate development positions, both domestic and international with Lederle Labs. Mr. Michel received an M.S. in microbiology and an M.B.A., both from the University of Rochester.

J
James Brown D.v.m
DURECT

James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.

H
Howard W. Robin
Nektar Therapeutics

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.

Stephan Kutzer is a Chief Executive Officer at CAMBRIDGE MAJOR LABORATORIES and Chief Executive Officer at AAIPharma Services. He has worked as COO:Pharma & Biotech Mkt Segment at Lonza America Inc., Head:Performance Chemicals at Lonza America Inc., and Assistant Production Manager at Lonza America Inc.. Stephan attended Technical University of Munich.

P
Patrick D. Walsh
Alcami

Wang Yan are a Chief Executive Officer at Cytovance Biologics, President at Scientific Protein Labs Llc, and Board Member at Cytovance Biologics. They have worked as VP:Business Development at Scientific Protein Labs Llc.

J
Jim Datin
BioAgilytix

E
Eric Smart
Coldstream Labs

Alliance Pharma Competitors FAQs

Search for jobs

Loading...